patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_507245 | REC_0007801 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 6.4 | 69 | female | 0 | 9 | 7.3 | 5 | entrectinib 600 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:58.767772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361240 | REC_0007802 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.7 | 64 | male | 0 | 26 | 7.1 | 2 | sotorasib 960 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:58.768033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714582 | REC_0007803 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 12.9 | 62 | male | 0 | 13 | 6.8 | 1 | osimertinib 80 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:58.768334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495107 | REC_0007804 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 8.6 | 73 | female | 2 | 14 | 7.8 | 7 | pembrolizumab 200 mg q3w | 6.6 | true | MSS | 2026-03-15T05:35:58.768575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564026 | REC_0007805 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 2.7 | 71 | female | 2 | 55 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:58.768819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693101 | REC_0007806 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 16.2 | 57 | female | 0 | 11 | 5.8 | 5 | entrectinib 600 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:35:58.769066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319949 | REC_0007807 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.9 | 64 | female | 0 | 15 | 4.1 | 5 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:58.769315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134973 | REC_0007808 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.9 | 68 | female | 0 | 44 | 7.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:35:58.769564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121638 | REC_0007809 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5 | 49 | male | 0 | 56 | 3.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.4 | true | MSS | 2026-03-15T05:35:58.769815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810202 | REC_0007810 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7 | 76 | female | 2 | 15 | 4.4 | 1 | pembrolizumab 200 mg q3w | 6.4 | true | MSS | 2026-03-15T05:35:58.770055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609414 | REC_0007811 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.6 | 84 | female | 2 | 17 | 6 | 6 | alectinib 600 mg BID | 13.2 | true | MSI-H | 2026-03-15T05:35:58.770301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914815 | REC_0007812 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 13.8 | 55 | female | 0 | 4 | 2.7 | 2 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:58.770553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267548 | REC_0007813 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.2 | 69 | female | 0 | 30 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:35:58.770795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685835 | REC_0007814 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9 | 71 | male | 2 | 20 | 4.3 | 6 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:58.771145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223948 | REC_0007815 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 8.6 | 64 | male | 1 | 12 | 6.2 | 0 | sotorasib 960 mg daily | 21.1 | false | MSS | 2026-03-15T05:35:58.771390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332962 | REC_0007816 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.2 | 64 | female | 0 | 17 | 8.1 | 5 | osimertinib 80 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:58.771640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790010 | REC_0007817 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 2.6 | 53 | male | 0 | 47 | 6.8 | 5 | pembrolizumab 200 mg q3w | 13.1 | true | MSS | 2026-03-15T05:35:58.771904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748164 | REC_0007818 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 13.8 | 79 | female | 2 | 22 | 5 | 5 | pembrolizumab 200 mg q3w | 11.4 | false | MSS | 2026-03-15T05:35:58.772314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366670 | REC_0007819 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 9.4 | 64 | female | 1 | 25 | 7.8 | 6 | entrectinib 600 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.772606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219795 | REC_0007820 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8.7 | 74 | female | 0 | 55 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:58.772843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987218 | REC_0007821 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 10.5 | 80 | male | 1 | 8 | 5 | 0 | alectinib 600 mg BID | 72.5 | false | MSI-H | 2026-03-15T05:35:58.773082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812071 | REC_0007822 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 4.6 | 59 | male | 1 | 18 | 3.8 | 6 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:58.773315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991992 | REC_0007823 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 11 | 4.4 | 71 | female | 2 | 30 | 3 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:58.773546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120461 | REC_0007824 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 17.5 | 52 | male | 0 | 14 | 5.5 | 1 | alectinib 600 mg BID | 20.1 | false | MSI-H | 2026-03-15T05:35:58.773783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651586 | REC_0007825 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 34 | 12.4 | 70 | male | 2 | 16 | 6.1 | 5 | pembrolizumab 200 mg q3w | 12.1 | true | MSI-H | 2026-03-15T05:35:58.774022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186649 | REC_0007826 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.3 | 61 | female | 1 | 16 | 3.8 | 9 | entrectinib 600 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:58.774257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829177 | REC_0007827 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.4 | 57 | male | 1 | 54 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:35:58.774586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387102 | REC_0007828 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 17.6 | 75 | female | 2 | 11 | 6.6 | 5 | osimertinib 80 mg daily | 5.2 | true | MSI-H | 2026-03-15T05:35:58.774821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241719 | REC_0007829 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.6 | 65 | female | 0 | 18 | 5.2 | 7 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:58.775059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146891 | REC_0007830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.7 | 70 | female | 2 | 24 | 5.9 | 6 | entrectinib 600 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:35:58.775295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829727 | REC_0007831 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 14.3 | 81 | female | 1 | 1 | 3.5 | 2 | osimertinib 80 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:35:58.775528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287363 | REC_0007832 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.6 | 72 | female | 2 | 70 | 5.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:35:58.775761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399635 | REC_0007833 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 3.7 | 69 | female | 0 | 36 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:58.775988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261831 | REC_0007834 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.7 | 56 | male | 0 | 13 | 6 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.776337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721094 | REC_0007835 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 16.4 | 74 | female | 1 | 28 | 4.9 | 8 | entrectinib 600 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:58.776574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216180 | REC_0007836 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 16.1 | 70 | female | 1 | 18 | 7.2 | 7 | alectinib 600 mg BID | 8 | true | MSI-H | 2026-03-15T05:35:58.776811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195686 | REC_0007837 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 7.5 | 68 | female | 1 | 15 | 7.6 | 3 | alectinib 600 mg BID | 8.5 | false | MSS | 2026-03-15T05:35:58.777044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994761 | REC_0007838 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4 | 57 | male | 1 | 32 | 3.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:58.777276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829940 | REC_0007839 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 5.9 | 79 | female | 2 | 30 | 6 | 5 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:58.777508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106187 | REC_0007840 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.1 | 66 | female | 1 | 41 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:58.777790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255035 | REC_0007841 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 11.6 | 83 | female | 2 | 12 | 6.5 | 4 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:58.778026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777906 | REC_0007842 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 10.6 | 76 | male | 2 | 16 | 7.4 | 0 | osimertinib 80 mg daily | 33.5 | true | MSI-H | 2026-03-15T05:35:58.778261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293992 | REC_0007843 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 17.1 | 68 | male | 1 | 12 | 4.6 | 4 | osimertinib 80 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:58.778499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384805 | REC_0007844 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 13.4 | 83 | female | 1 | 16 | 5.1 | 2 | entrectinib 600 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.778737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872663 | REC_0007845 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 10.4 | 55 | male | 0 | 18 | 5.1 | 4 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:58.778986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978083 | REC_0007846 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.5 | 61 | female | 1 | 7 | 4 | 3 | alectinib 600 mg BID | 9.2 | false | MSI-H | 2026-03-15T05:35:58.779233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141391 | REC_0007847 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 9.5 | 75 | female | 0 | 15 | 4.1 | 0 | alectinib 600 mg BID | 39.7 | true | MSS | 2026-03-15T05:35:58.779480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623112 | REC_0007848 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 18.1 | 64 | female | 0 | 16 | 4.5 | 4 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:58.779727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930978 | REC_0007849 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.8 | 64 | female | 1 | 42 | 7.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:58.779972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377515 | REC_0007850 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 7.5 | 61 | female | 1 | 44 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:58.780265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244525 | REC_0007851 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.6 | 90 | female | 1 | 50 | 7.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:35:58.780522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218659 | REC_0007852 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 3.8 | 66 | female | 0 | 59 | 5.4 | 7 | pembrolizumab 200 mg q3w | 11.6 | true | MSS | 2026-03-15T05:35:58.780768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972987 | REC_0007853 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 5.8 | 64 | female | 1 | 14 | 5.7 | 8 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.781122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980464 | REC_0007854 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 7.4 | 81 | female | 2 | 25 | 5.3 | 1 | sotorasib 960 mg daily | 25.4 | false | MSS | 2026-03-15T05:35:58.781372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299028 | REC_0007855 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.3 | 55 | male | 0 | 11 | 3.5 | 2 | osimertinib 80 mg daily | 23.4 | false | MSI-H | 2026-03-15T05:35:58.781612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336272 | REC_0007856 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.3 | 74 | female | 2 | 87 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 5 | false | MSS | 2026-03-15T05:35:58.781844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203668 | REC_0007857 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 1.7 | 66 | male | 0 | 15 | 7.5 | 2 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:35:58.782077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503530 | REC_0007858 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 16.7 | 72 | female | 2 | 8 | 4.7 | 2 | osimertinib 80 mg daily | 19.8 | false | MSS | 2026-03-15T05:35:58.782309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956114 | REC_0007859 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 16.6 | 56 | male | 0 | 27 | 5.6 | 5 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:58.782544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324363 | REC_0007860 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.8 | 74 | female | 2 | 22 | 4.2 | 7 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:58.782784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614058 | REC_0007861 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 10.5 | 60 | female | 0 | 14 | 2.8 | 4 | pembrolizumab 200 mg q3w | 6.2 | false | MSI-H | 2026-03-15T05:35:58.783021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419871 | REC_0007862 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.7 | 74 | female | 1 | 40 | 6.5 | 7 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:35:58.783252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915856 | REC_0007863 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 16.6 | 70 | male | 1 | 9 | 6.1 | 0 | osimertinib 80 mg daily | 35 | false | MSS | 2026-03-15T05:35:58.783490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443121 | REC_0007864 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.8 | 75 | female | 2 | 11 | 6.2 | 3 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.783721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418637 | REC_0007865 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 8.3 | 90 | female | 3 | 21 | 6.8 | 6 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:58.783953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290619 | REC_0007866 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 18.9 | 64 | male | 0 | 15 | 5.1 | 0 | alectinib 600 mg BID | 24.4 | true | MSS | 2026-03-15T05:35:58.784312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558352 | REC_0007867 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14.1 | 69 | male | 0 | 20 | 3.7 | 1 | osimertinib 80 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:58.784571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984133 | REC_0007868 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 15 | 11.6 | 63 | male | 0 | 16 | 5.2 | 2 | entrectinib 600 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.784809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366217 | REC_0007869 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 8.7 | 62 | male | 0 | 6 | 3.3 | 2 | osimertinib 80 mg daily | 27.8 | true | MSS | 2026-03-15T05:35:58.785043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137793 | REC_0007870 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.3 | 68 | female | 1 | 14 | 5.2 | 2 | alectinib 600 mg BID | 16.6 | true | MSS | 2026-03-15T05:35:58.785276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210217 | REC_0007871 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.6 | 66 | male | 0 | 27 | 6.4 | 6 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:58.785512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564729 | REC_0007872 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 8 | 70 | male | 0 | 57 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.5 | true | MSS | 2026-03-15T05:35:58.785746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841180 | REC_0007873 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 6 | 59 | female | 0 | 17 | 4.3 | 2 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.785978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598130 | REC_0007874 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 2.9 | 74 | female | 2 | 9 | 6 | 2 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:35:58.786207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843814 | REC_0007875 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.7 | 78 | male | 1 | 13 | 5.8 | 8 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:58.786439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234128 | REC_0007876 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.7 | 74 | male | 2 | 13 | 4 | 4 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.786668+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680875 | REC_0007877 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.1 | 62 | male | 0 | 69 | 8.7 | 4 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:58.786899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234126 | REC_0007878 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.8 | 51 | male | 0 | 14 | 3.8 | 2 | alectinib 600 mg BID | 26.9 | true | MSI-H | 2026-03-15T05:35:58.787131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560283 | REC_0007879 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18.2 | 72 | female | 2 | 10 | 4.3 | 9 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.787409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683822 | REC_0007880 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 8.7 | 71 | female | 1 | 16 | 4.2 | 8 | alectinib 600 mg BID | 11.2 | true | MSS | 2026-03-15T05:35:58.787642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416568 | REC_0007881 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.5 | 64 | male | 0 | 23 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.2 | true | MSS | 2026-03-15T05:35:58.787874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882104 | REC_0007882 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 18.5 | 55 | male | 0 | 11 | 5.5 | 6 | sotorasib 960 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:58.788141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861425 | REC_0007883 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 9.6 | 69 | male | 0 | 7 | 6.5 | 1 | osimertinib 80 mg daily | 30.3 | true | MSS | 2026-03-15T05:35:58.788379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334799 | REC_0007884 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 15.1 | 56 | male | 0 | 10 | 4.2 | 4 | sotorasib 960 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.788620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872613 | REC_0007885 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.6 | 51 | male | 0 | 15 | 7.7 | 2 | entrectinib 600 mg daily | 24.3 | true | MSI-H | 2026-03-15T05:35:58.788855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515513 | REC_0007886 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 7.7 | 68 | male | 0 | 65 | 4.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:58.789088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152023 | REC_0007887 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 2.5 | 73 | female | 1 | 17 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 21 | true | MSS | 2026-03-15T05:35:58.789318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727026 | REC_0007888 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 10.9 | 76 | female | 1 | 13 | 5.4 | 2 | osimertinib 80 mg daily | 31.8 | true | MSS | 2026-03-15T05:35:58.789550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433665 | REC_0007889 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 18 | 10.3 | 74 | female | 1 | 19 | 6.6 | 2 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:35:58.789782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616439 | REC_0007890 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 18 | 69 | male | 1 | 16 | 4.5 | 2 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:35:58.790017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416458 | REC_0007891 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.1 | 61 | male | 1 | 17 | 6 | 7 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:58.790253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600225 | REC_0007892 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.1 | 72 | female | 2 | 20 | 5.8 | 7 | osimertinib 80 mg daily | 6.6 | false | MSI-H | 2026-03-15T05:35:58.790536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712793 | REC_0007893 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 11.3 | 81 | female | 2 | 9 | 4.2 | 2 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:58.790773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729666 | REC_0007894 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.7 | 69 | female | 1 | 20 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.2 | true | MSS | 2026-03-15T05:35:58.791000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430810 | REC_0007895 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10.4 | 57 | female | 1 | 15 | 5.6 | 1 | entrectinib 600 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:35:58.791238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788970 | REC_0007896 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.4 | 73 | male | 2 | 73 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.1 | true | MSS | 2026-03-15T05:35:58.791469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275699 | REC_0007897 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 6.8 | 76 | male | 2 | 18 | 4.5 | 2 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:58.791701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366943 | REC_0007898 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 9.6 | 58 | female | 0 | 14 | 4.7 | 0 | alectinib 600 mg BID | 43.7 | false | MSS | 2026-03-15T05:35:58.791933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217272 | REC_0007899 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 15.7 | 68 | female | 1 | 27 | 4.9 | 2 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:58.792190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941933 | REC_0007900 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15.2 | 66 | female | 1 | 11 | 6.1 | 5 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:58.792426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.